Traws Pharma, Inc.
TRAW
$2.00
$0.2514.29%
| Weiss Ratings | TRAW - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | TRAW - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TRAW - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.34 | |||
| Price History | TRAW - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -13.79% | |||
| 30-Day Total Return | -39.58% | |||
| 60-Day Total Return | -70.82% | |||
| 90-Day Total Return | -56.33% | |||
| Year to Date Total Return | -76.93% | |||
| 1-Year Total Return | -89.83% | |||
| 2-Year Total Return | -88.11% | |||
| 3-Year Total Return | -95.24% | |||
| 5-Year Total Return | -98.38% | |||
| 52-Week High % Change | -91.57% | |||
| 52-Week Low % Change | 15.13% | |||
| Price | TRAW - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $20.75 | |||
| 52-Week Low Price | $1.52 | |||
| 52-Week Low Price (Date) | Apr 09, 2025 | |||
| 52-Week High Price (Date) | Apr 11, 2024 | |||
| Valuation | TRAW - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 8.88M | |||
| Enterprise Value | -12.46M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -109.76 | |||
| Earnings Per Share Growth | 386.28% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 23.87 | |||
| Price/Book (Q) | -0.20 | |||
| Enterprise Value/Revenue (TTM) | -55.13 | |||
| Price | $2.00 | |||
| Enterprise Value/EBITDA (TTM) | 0.50 | |||
| Enterprise Value/EBIT | 0.50 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | TRAW - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 3.08M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TRAW - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 267 759 3680 | |||
| Address | 12 Penns Trail Newtown, PA 18940 | |||
| Website | www.trawspharma.com | |||
| Country | United States | |||
| Year Founded | 1998 | |||
| Profitability | TRAW - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -11,022.12% | |||
| Profit Margin | -73,682.74% | |||
| Management Effectiveness | TRAW - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -65.35% | |||
| Return on Equity | -- | |||
| Income Statement | TRAW - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 226.00K | |||
| Total Revenue (TTM) | 226.00K | |||
| Revenue Per Share | $0.07 | |||
| Gross Profit (TTM) | 226.00K | |||
| EBITDA (TTM) | -24.90M | |||
| EBIT (TTM) | -24.91M | |||
| Net Income (TTM) | -166.52M | |||
| Net Income Avl. to Common (TTM) | -166.52M | |||
| Total Revenue Growth (Q YOY) | 0.00% | |||
| Earnings Growth (Q YOY) | -615.15% | |||
| EPS Diluted (TTM) | -109.76 | |||
| EPS Diluted Growth (Q YOY) | 634.44% | |||
| Balance Sheet | TRAW - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 21.34M | |||
| Cash Per Share (Q) | $6.93 | |||
| Total Current Assets (Q) | 24.95M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -31.63M | |||
| Current Ratio (Q) | 2.163 | |||
| Book Value Per Share (Q) | -$8.66 | |||
| Total Assets (Q) | 24.96M | |||
| Total Current Liabilities (Q) | 11.53M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 56.59M | |||
| Total Common Equity (Q) | -31.63M | |||
| Cash Flow | TRAW - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -3.65M | |||
| Cash from Financing (TTM) | 33.98M | |||
| Net Change in Cash (TTM) | 517.00K | |||
| Levered Free Cash Flow (TTM) | -13.63M | |||
| Cash from Operations (TTM) | -29.79M | |||
